Mintz advised Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, in its recently announced research collaboration and license option agreement with Takeda Pharmaceutical Company Limited to discover, develop and commercialize transformative cell therapies in rare inherited metabolic disorders with central nervous system manifestations and complications using Immusoft’s Immune System Programming (ISP™) technology platform. The collaboration will focus on delivering protein therapeutics across the blood-brain barrier, a promising area of Immusoft’s research, which has the potential to enable the treatment of diseases with high unmet need. Under the terms of the agreement, Immusoft will receive an undisclosed upfront payment and research funding support. The company is also eligible to receive future option fees and milestone payments with a total potential value of more than $900 million.
Based in Seattle, Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using a sustained delivery of protein therapeutics from a patient’s own cells. The company’s ISP technology platform modifies a patient’s B cells and instructs the cells to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to persist for many years.
Mintz is one of the leading law firms to the life sciences industry. The firm’s attorneys advise hundreds of businesses and other organizations across the sector’s ecosystem—from start-ups and emerging growth companies to large public companies as well as venture capital firms, investment banks, and research and academic institutions—on pivotal deals, mission-critical disputes, intellectual property, and regulatory matters. Learn more about Mintz’s Life Sciences Practice here.